Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a streamlined evaluation by the lead team of committee B, which includes the chair.

Betula verrucosa (Itulazax 12 SQ-Bet) is available on the NHS. It is a possible treatment for moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy ...

This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This ...

What the quality statement means for different audiences Service providers (including health promotion services, primary care, behavioural overweight and obesity management services) ensure that their ...

Our tool to help you plan for and implement NICE guidance. Use it to: View upcoming NICE guidance including proposed consultation dates. Understand the resource implications (both financial and ...